# A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets

> **NCT06165822** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Malignant Neoplasm

## Interventions

- **DRUG:** TQB3909 tablets
- **DRUG:** Itraconazole capsule
- **DRUG:** Rifampicin capsule

## Key facts

- **NCT ID:** NCT06165822
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2024-01
- **Final completion:** 2024-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06165822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06165822, "A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06165822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*